News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Amazon launched AI hiring tools and a 'humorphism' design, and released Quick desktop assistant to index files and automate workplace workflows.
  • NVIDIA introduced Nemotron 3 Nano Omni, a multimodal model that ingests text, images, audio and video for enterprise deployment.
  • The FCC plans expedited reviews of eight ABC stations, raising potential license revocation risk for Disney’s broadcast operations.
  • Kim Jong Un publicly praised North Korean soldiers who committed suicide while fighting in Russia's Kursk region.
  • The World Bank warned Uganda's draft foreign funding law could criminalize routine operations of international organizations.
  • U.S. pump prices rose toward a near four-year high as crude strength and Midwest refinery outages tightened supply.
  • European equities were mixed: Madrid, Milan and Lisbon closed higher while Amsterdam, Frankfurt, Paris and Brussels finished lower.

Latest Articles

Hackers Claim Access to FBI Director’s Personal Email; DOJ Confirms Compromise

Hackers Claim Access to FBI Director’s Personal Email; DOJ Confirms Compromise

Iran-linked hackers identified as the Handala Hack Team published photos and a purported resume tied to the personal email account of the FBI director and said his name would be added to its list of victims. A Justice Department official confirmed the director's emails were compromised but would not elaborate. Independent authentication and the ful…

Alvopetro Upgrade: Buy the Yield, Ride the Oil Tailwind

Alvopetro Upgrade: Buy the Yield, Ride the Oil Tailwind

Alvopetro (ALVOF) looks attractive as a yield-oriented trade after crude strength and improving technicals. The stock is trading around $6.86 with bullish momentum (RSI ~76, MACD positive) and light short interest. For income-focused traders willing to accept OTC liquidity risk, this is a tactical long with an entry at $6.86, stop at $6.00 and a pr…

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

Celldex Therapeutics presented positive Phase 2 clinical trial results for barzolvolimab in chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) at the 2026 AAD Annual Meeting. The data demonstrated rapid, profound, and durable improvements in patient quality of life across multiple domains, with sustained…

Argentina Wins Reversal of $16.1 Billion YPF Judgment

Argentina Wins Reversal of $16.1 Billion YPF Judgment

A U.S. federal appeals court on Friday overturned a $16.1 billion judgment tied to Argentina's 2012 nationalization of YPF SA, ruling that a Manhattan judge erred in deciding for former shareholders. The lawsuit had backing from litigation funder Burford Capital Ltd., which had stood to receive a significant share of any award. The decision elimina…

Deutsche Bank: Private Credit Keeps Pressure on Boutique Advisory Firms

Deutsche Bank: Private Credit Keeps Pressure on Boutique Advisory Firms

Deutsche Bank analysts warn that private credit - especially direct lending - continues to weigh on middle-market mergers and acquisitions, creating persistent headwinds for boutique advisory firms whose deal flow relies heavily on sponsor-backed transactions. The bank highlights measurement challenges around private credit usage, its outsized role…

Visma Defers IPO to 2027 as Market Headwinds Persist

Visma Defers IPO to 2027 as Market Headwinds Persist

Visma AS, the privately held software company backed by private equity firm Hg, has pushed its planned initial public offering into 2027, according to Bloomberg. The business had earlier shifted a 2026 IPO to October after a selloff in technology shares tied to AI concerns and is now unlikely to list this year. Visma had provisionally selected Lond…

Two COSCO Container Vessels Turn Back After Attempt to Transit Strait of Hormuz

Two COSCO Container Vessels Turn Back After Attempt to Transit Strait of Hormuz

Two Hong Kong-flagged container ships operated by China’s COSCO attempted to leave the Gulf through the Strait of Hormuz but turned back shortly after beginning the transit, ship-tracking data shows. The incident occurred despite a statement from Iran saying it had allowed passage for friendly nations including China. The move was the first recorde…

Meta at These Levels Is a Buy: 16x Out-Year EPS Understates the Upside

Meta at These Levels Is a Buy: 16x Out-Year EPS Understates the Upside

Meta’s stock has been beaten down with the broader tech sell-off, but an 18% earnings-growth cadence implies out-year EPS near $33.3. Applying a conservative 16x multiple to that out-year EPS is roughly the current price, while a modest multiple rerating to 20x implies material upside to $660. Technicals are deeply oversold and an Arm partnership p…

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Aclaris Therapeutics presented additional positive Phase 2a clinical trial results for ATI-2138, an investigational oral inhibitor targeting ITK and JAK3, showing significant improvements in atopic dermatitis severity, itch, and quality of life. The therapy demonstrated strong efficacy and tolerability, supporting its potential in treating immuno-i…

Buy JQC as a High-Yield Fed-Rate Hedge - Upgrade to Long (Position Trade)

Buy JQC as a High-Yield Fed-Rate Hedge - Upgrade to Long (Position Trade)

Nuveen Credit Strategies Income Fund (JQC) pays a 13.7% yield, trades near its 52-week low, and holds primarily adjustable-rate senior loans. If the Federal Reserve pauses or refrains from cutting rates, JQC's floating-rate exposure and rich distribution make it a useful hedge. This trade upgrades JQC to a buy for a mid-term position (45 trading da…